SCHEMBL4690915

SCHEMBL4690915

COc1ccc(NC2=C(c3ccccc3)C(=O)N(Cc3ccc(N)nc3)C2=O)cc1

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 9/20 0.73
NR1H3 Q13133 9/20 0.73
MAPT P10636 4/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NAMPT P43490 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CASP3 P42574 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GSK3B P49841 1/20 0.40
NPBWR1 P48145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5745684 0.89 NR1H2 (0.58) NR1H2NR1H3MAPTSMN1; SMN2NAMPT
SCHEMBL4684834 0.87 NR1H2 (0.55) NR1H2NR1H3MAPTNAMPTMEN1
SCHEMBL4450601 0.85 NR1H2 (1.00) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL5746701 0.84 NR1H2 (0.53) NR1H2NR1H3MAPTSMN1; SMN2
SCHEMBL4688066 0.84 NR1H2 (0.80) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL5745530 0.83 NR1H2 (0.78) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL4686588 0.82 NR1H2 (0.85) NR1H2NR1H3MAPTSMN1; SMN2MEN1
SCHEMBL4690096 0.81 NR1H2 (0.51) NR1H2NR1H3MAPTNAMPTALDH1A1
SCHEMBL4693569 0.81 NR1H2 (0.81) NR1H2NR1H3MAPTSMN1; SMN2CASP3
SCHEMBL4692898 0.81 NR1H2 (0.81) NR1H2NR1H3MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432288-B2 Pyrrole-2,5-dione derivatives as Liver X receptor modulators ASTRAZENECA AB (SE) 2008-10-07 US claimed
EP-1646626-B1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2008-07-02 EP claimed
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators ASTRAZENECA AB (SE) 2006-10-19 US claimed
US-7432288-B2 Pyrrole-2,5-dione derivatives as Liver X receptor modulators ASTRAZENECA AB (SE) 2008-10-07 US disclosed
EP-1646626-B1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2008-07-02 EP disclosed
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators ASTRAZENECA AB (SE) 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators NR1H2, NR1H3, SREBF2 NR1H2 1/4885NR1H3 2/4885MAPT 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.